相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis
Britta Hahn
SCHIZOPHRENIA BULLETIN (2018)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Ashleigh L. Osborne et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Cannabidiol: State of the art and new challenges for therapeutic applications
Simona Pisanti et al.
PHARMACOLOGY & THERAPEUTICS (2017)
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease
Georgia Watt et al.
FRONTIERS IN PHARMACOLOGY (2017)
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders
Jonathan L. C. Lee et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Evidences for the Anti-panic Actions of Cannabidiol
Vanessa P. Soares et al.
CURRENT NEUROPHARMACOLOGY (2017)
The cannabis withdrawal syndrome: current insights
Udo Bonnet et al.
SUBSTANCE ABUSE AND REHABILITATION (2017)
Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents
Pius S. Fasinu et al.
PHARMACOTHERAPY (2016)
Does cannabidiol have a role in the treatment of schizophrenia?
Anand Gururajan et al.
SCHIZOPHRENIA RESEARCH (2016)
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction
Maria Rodriguez-Munoz et al.
ONCOTARGET (2016)
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
P. Seeman
TRANSLATIONAL PSYCHIATRY (2016)
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R. B. Laprairie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
Alexandre R. de Mello Schier et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2014)
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings
Celia J. A. Morgan et al.
ADDICTIVE BEHAVIORS (2013)
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report
J. A. S. Crippa et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Alline Cristina Campos et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Regulation of nausea and vomiting by cannabinoids
Linda A. Parker et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
Jose Alexandre S. Crippa et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Cannabidiol was ineffective for manic episode of bipolar affective disorder
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Jaime E. C. Hallak et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2010)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Endocannabinoids and the regulation of their levels in health and disease
Vincenzo Di Marzo et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Cannabidiol monotherapy for treatment-resistant schizophrenia
Antonio Waldo Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Agonistic properties of cannabidiol at 5-HT1a receptors
EB Russo et al.
NEUROCHEMICAL RESEARCH (2005)
分享论文
